A Multicenter, Multi-Arm, Randomized, Multi-Dose, Placebo-Controlled, Double-Blind, Phase 3 Study of Intravesical Apaziquone (EOquin) as a Surgical Adjuvant in the Immediate Postoperative Period in Patients Undergoing TURBT
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 07 Dec 2016
At a glance
- Drugs Apaziquone (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- Sponsors Spectrum Pharmaceuticals
- 27 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 26 Oct 2015 According to a Spectrum Pharmaceuticals media release, the first patient has been dosed in this trial.
- 13 Oct 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.